[1] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8（6）：324-329.
[2] Armstrong GL,Wasley A,Simard EP,et al. The prevalence of hepatitis C virus infection in the United states,1999 through 2002. Ann Intern Med,2006,144 （10）:705-714.
[3] Yoshizawa H,Tanaka J,Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology,2006,49（1-2）:7-17.
[4] Hoshida Y,Ikeda K,Kobayashi M,et al. Chronic liver disease in the extremely elderly of 80 years or more:clinical characteristics,prognosis and patient survival analysis. J Hepatol,1999,31（5）:860-866.
[5] Thabut D,Le Calvez S,Thibault V,et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease Am J Gastroenterol,2006,101（6）:1260-1267
[6] Arase Y,Ikeda K,Suzuki F,Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology,2007,50（1）:16-23.
[7] Ikeda K,Arase Y,Kawamura Y,et al. Necessities of interferon therapy in elderly patients with chronic hepatitis C. Am J Med,2009,122（5）:479-486.
[8] Imai Y,Kasahara A,Tanaka H,et al. Interferon therapy for aged patients with chronic hepatitis C:improved survival in patients exhibiting a biochemical response. J Gastroenterol,2004,39（11）:1069-1077.
[9] Honda T,Katano Y,Shimizu J,et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.Liver Int,2010,30（4）:527-537.
[10] Floreani A,Minola E,Carderi I,et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C J Am Geriatr Soc,2006,54（3）:549-550.
[11] Fried MW,Shiffman ML,Reddy KR,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med,2002,347（13）:975-982.
[12] Manns MP,McHutchison JG,ordon SC,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet,2001,358（9286）:958-965.
[13] Huang CF,Yang JF,Dai CY,et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.J Infect Dis,2010,201（5）:751-759.
[14] McHutchison JG,Gordon SC,Schiff ER,et al.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med,1998,339（21）:1485-1492.
[15] Shehab TM,Fontana RJ,Oberhelman K,et al. Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice.Clin Gastroenterol Hepatol,2004,2（5）:425-431.
[16] Iwasaki Y,Ikeda H,Araki Y,et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology,2006,43（1）:54-63
[17] Nudo CG,Wong P,Hilzenrat N,et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol,2006,20（9）:589-592.
[18] Sezaki H,Suzuki F,Kawamura Y,et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci,2009,54（6）:1317-1324.
[19] Reddy KR,Messinger D,Popescu M,et al. Peginterferon alpha-2a（40 kDa）and ribavirin:comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat,2009,16（10）:724-731.
[20] Davis GL,Wong JB,McHutchison JG,et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology,2003,38（3）:645-652.
[21] Shiffman ML,Di Bisceglie AM,Lindsay KL,et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology,2004,126（4）:1015-1023.
[22] Hadziyannis SJ,Sette H,Morgan TR,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose.Ann Intern Med,2004,140（5）:346-355.
[23] Afdhal NH,Dieterich DT,Pockros PJ,et al. Epoetin alfa maintains ribavirin dose in HCV-in- fected patients:a prospective,double-blind,randomized controlled study. Gastroenterology,2004,126（5）:1302-1311.
[24] Collantes RS,Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol,2005,39（Suppl 1）:S9-S13.
[25] Watson J. Prospects for hepatitis C virus therapeutics:levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Invest Drugs,2002,3（5）:680-683.
[26] Lamarre D,Anderson PC,Bailey M,et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature,2003,426（6963）:186-189.
[27] Kwo PY. Boceprevir:a novel nonstructural 3（NS3）protease inhibitor for the treatment of chronic hepatitis C infection. Therap Adv Gastroenterol,2012,5（3）:179-188. |
